[go: up one dir, main page]

AR014514A1 - AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCE - Google Patents

AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCE

Info

Publication number
AR014514A1
AR014514A1 ARP990100346A ARP990100346A AR014514A1 AR 014514 A1 AR014514 A1 AR 014514A1 AR P990100346 A ARP990100346 A AR P990100346A AR P990100346 A ARP990100346 A AR P990100346A AR 014514 A1 AR014514 A1 AR 014514A1
Authority
AR
Argentina
Prior art keywords
polinucleotide
isolated
polypeptide
expression vector
polynucleotides
Prior art date
Application number
ARP990100346A
Other languages
Spanish (es)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AR014514A1 publication Critical patent/AR014514A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Polinucleotidos aislados que codifican polipéptidos de tumor de pulmon. Estos polinucleotidos comprenden una secuencia de nucleotidos seleccionada delgrupo consistente en: (a) secuencias provistas en SEQ. ID. NO.: 1-11, 19, 22- 25, 27-31, 51, 53, 55, 63, 70, 72, 79, 80, 86, 87, 89, 90, 102-107, 109, 139,143-149, 151-154, y 156-158; (b) secuencias complementarias para una secuencia provista en SEQ. ID. NO.: 1-11, 19, 22-25, 27-31, 51, 53, 55, 63, 70, 72, 79,80, 86, 89, 90, 102-107, 109, 139, 143-149, 151-154, y 156-158; y (c) variantes de las secuencias de (a) y (b). Los polipéptidos aislados comprenden al menosuna porcion inmunogénica de una proteína de tumor pulmonar, o de una variante de ella. Vectores de expresion que comprendenlos polinucleotidos; célulashuéspedes transformadas o transinfectadas con estos vectores de expresion. Las proteínas de fusion comprenden un primer y un segundo polipéptido, o bien, elpolipéptido y un antígeno de tumor de pulmon conocido. Las composiciones farmacéuticas comprenden uno o más de los polipéptidos codificados por unpolinucleotido que comprende una secuencia seleccionada del grupo que consiste de (a) secuencias provistas en SEQ. ID. NO.: 1 a 181; (b) complementos de lassecuencias provistas en SEQ. ID. NO.: 1 a 181; (c) variantes de las secuencias de (a) y (b); proteínas de fusion, o polinucleotidos, y un vehículofisiologicamente aceptable. Las vacunas comprenden uno o más de los polipéptidos, proteínas de fusion, o polinucleotidos, combinados con unmejorador de respuesta inmune. Los métodos para inhibir el desarrollo de cáncer de pulmon en un paciente consisten en administrar a un paciente una cantidadeficaz de al menos una de las composiciones farmacéuticas y/o vacunas mencionadas. Métodos para detectar cáncer de pulmon en un paciente consisten enIsolated polynucleotides encoding lung tumor polypeptides. These polynucleotides comprise a nucleotide sequence selected from the group consisting of: (a) sequences provided in SEQ. ID. NO .: 1-11, 19, 22-25, 27-31, 51, 53, 55, 63, 70, 72, 79, 80, 86, 87, 89, 90, 102-107, 109, 139,143-149 , 151-154, and 156-158; (b) complementary sequences for a sequence provided in SEQ. ID. NO .: 1-11, 19, 22-25, 27-31, 51, 53, 55, 63, 70, 72, 79.80, 86, 89, 90, 102-107, 109, 139, 143-149 , 151-154, and 156-158; and (c) variants of the sequences of (a) and (b). Isolated polypeptides comprise at least one immunogenic portion of a lung tumor protein, or a variant thereof. Expression vectors comprising polynucleotides; Guests transformed or transinfected with these expression vectors. Fusion proteins comprise a first and a second polypeptide, or the polypeptide and a known lung tumor antigen. The pharmaceutical compositions comprise one or more of the polypeptides encoded by a polynucleotide comprising a sequence selected from the group consisting of (a) sequences provided in SEQ. ID. NO .: 1 to 181; (b) complements of the sequences provided in SEQ. ID. NO .: 1 to 181; (c) variants of the sequences of (a) and (b); fusion proteins, or polynucleotides, and a physiologically acceptable vehicle. Vaccines comprise one or more of the polypeptides, fusion proteins, or polynucleotides, combined with an immune response enhancer. The methods for inhibiting the development of lung cancer in a patient consist in administering to a patient an effective amount of at least one of the pharmaceutical compositions and / or vaccines mentioned. Methods to detect lung cancer in a patient consist of

ARP990100346A 1998-01-28 1999-01-28 AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCE AR014514A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US1502298A 1998-01-28 1998-01-28
US1502998A 1998-01-28 1998-01-28
US4082898A 1998-03-18 1998-03-18
US4083198A 1998-03-18 1998-03-18
US12219198A 1998-07-23 1998-07-23
US12219298A 1998-07-23 1998-07-23
US21924598A 1998-12-22 1998-12-22

Publications (1)

Publication Number Publication Date
AR014514A1 true AR014514A1 (en) 2001-02-28

Family

ID=27567530

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100346A AR014514A1 (en) 1998-01-28 1999-01-28 AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCE

Country Status (13)

Country Link
EP (1) EP1051489A2 (en)
JP (1) JP2002516659A (en)
KR (1) KR20010034436A (en)
CN (1) CN1292029A (en)
AR (1) AR014514A1 (en)
AU (1) AU2344399A (en)
BR (1) BR9907259A (en)
CA (1) CA2319117A1 (en)
ID (1) ID27813A (en)
IL (1) IL137417A0 (en)
NO (1) NO20003853L (en)
WO (1) WO1999038973A2 (en)
ZA (1) ZA99693B (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6312695B1 (en) 1998-03-18 2001-11-06 Corixa Corporation Compounds and methods for therapy of lung cancer
US6531315B1 (en) 1998-03-18 2003-03-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6426072B1 (en) 2000-08-02 2002-07-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6696247B2 (en) 1998-03-18 2004-02-24 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6660838B1 (en) 1998-03-18 2003-12-09 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6482597B1 (en) 1999-12-17 2002-11-19 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6821518B1 (en) 1998-03-18 2004-11-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7049063B2 (en) 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US6518256B1 (en) 1998-03-18 2003-02-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
EP1526383A3 (en) * 1998-08-31 2005-11-16 Pfizer Products Inc. Diarylsulfonylurea binding proteins
EP0987552A3 (en) 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
WO2000026241A2 (en) * 1998-10-28 2000-05-11 Rigel Pharmaceuticals, Inc. Novel compositions and methods of screening for t-cell and b-cell activation modulators
WO2000035473A2 (en) * 1998-12-18 2000-06-22 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
US6709855B1 (en) 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
WO2000046370A1 (en) * 1999-02-04 2000-08-10 Board Of Trustees Of The University Of Illinois P37ing1 compositions and methods of use
CZ20012916A3 (en) 1999-02-19 2002-05-15 Zymogenetics, Inc. Pharmaceutical preparation
US6544946B1 (en) 1999-02-19 2003-04-08 Zymogenetics, Inc. Inhibitors for use in hemostasis and immune function
JP2002540790A (en) * 1999-04-02 2002-12-03 コリクサ コーポレイション Compounds for the treatment and diagnosis of lung cancer and methods for their use
US6759508B2 (en) 2000-09-01 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
ATE399793T1 (en) * 1999-04-02 2008-07-15 Corixa Corp COMPOUNDS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
US20030125245A1 (en) 1999-06-30 2003-07-03 Tongtong Wang Compositions and methods for therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6914132B1 (en) 1999-06-30 2005-07-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2380873A1 (en) 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6509448B2 (en) 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6746846B1 (en) 1999-06-30 2004-06-08 Corixa Corporation Methods for diagnosing lung cancer
US6667154B1 (en) 1999-06-30 2003-12-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
AU7832700A (en) * 1999-09-23 2001-04-24 Corixa Corporation Ovarian tumor antigen and methods of use therefor
EP1690872A3 (en) * 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
EP1272511A2 (en) * 2000-04-14 2003-01-08 Incyte Genomics, Inc. Molecules associated with human reproduction
CA2414596A1 (en) * 2000-06-29 2002-01-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2002004514A2 (en) * 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2001270638A1 (en) * 2000-07-19 2002-01-30 Bayer Aktiengesellschaft Regulation of human airway trypsin protease-like enzyme
TWI317380B (en) * 2000-08-28 2009-11-21 Teijin Ltd Airway-specific trypsin-like enzymes and method of using the same
WO2002055694A2 (en) 2001-01-16 2002-07-18 Genset Sa Discriminative nucleic acid analysis using clone sequence signatures
GB0101300D0 (en) * 2001-01-18 2001-02-28 Univ Cambridge Tech Primordial germ cell genes
US7226994B2 (en) 2001-01-18 2007-06-05 Cambridge University Technical Services Limited Cell surface expressed marker of pluripotency
US20050085627A1 (en) 2001-06-21 2005-04-21 Youming Zhang Atopy
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AU2007216892B2 (en) * 2002-08-16 2011-02-10 Agensys, Inc. Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
AU2003296330A1 (en) * 2002-12-10 2004-06-30 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
BRPI0518734A2 (en) * 2004-11-30 2008-12-02 Veridex Llc prognosis of lung cancer
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007120673A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
EP2061900A2 (en) * 2006-08-25 2009-05-27 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
EP2334826A4 (en) * 2008-09-12 2012-01-25 Cancer Res Initiative Foundation METHOD FOR DETECTION AND DIAGNOSIS OF ORAL AND RHINO-PHARYNGIAN CANCERS
CN101891802B (en) * 2009-08-11 2011-11-16 武汉凯泰新生物技术有限公司 Polypeptide or derivative product for treating or preventing cancer and application thereof
CN101921313B (en) * 2010-04-07 2012-02-29 武汉凯泰新生物技术有限公司 Polypeptide for curing or preventing cancer or derivative product and application thereof
GB201104286D0 (en) * 2011-03-15 2011-04-27 Randox Lab Ltd Glutathione S-transferase omega 1 wild type specific antibody
EP2754713B1 (en) * 2011-09-09 2019-07-10 Trans Genic Inc. ANTIBODY AGAINST MUTANT alpha-ACTININ-4
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
PL2945647T3 (en) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN109476721B (en) * 2016-04-04 2022-06-28 英蒂分子公司 CD8-specific capture agents, compositions and methods of use and preparation
CA3042880A1 (en) * 2016-11-16 2018-05-24 The Regents Of The University Of California Inhibitors of crispr-cas9
CN110669104B (en) * 2019-10-30 2021-11-05 上海交通大学 A group of markers derived from human peripheral blood mononuclear cells and their applications
CN112500467B (en) * 2020-12-14 2022-05-24 上海交通大学 Bioactive peptide RRECPSDECGAGVF, and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor

Also Published As

Publication number Publication date
CA2319117A1 (en) 1999-08-05
KR20010034436A (en) 2001-04-25
NO20003853D0 (en) 2000-07-27
CN1292029A (en) 2001-04-18
JP2002516659A (en) 2002-06-11
NO20003853L (en) 2000-09-27
ZA99693B (en) 1999-10-21
WO1999038973A3 (en) 1999-12-09
EP1051489A2 (en) 2000-11-15
ID27813A (en) 2001-04-26
WO1999038973A2 (en) 1999-08-05
IL137417A0 (en) 2001-07-24
AU2344399A (en) 1999-08-16
BR9907259A (en) 2002-01-22

Similar Documents

Publication Publication Date Title
AR014514A1 (en) AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCE
TWI285648B (en) Compositions and methods for WT1 specific immunotherapy
AR032173A1 (en) CRYPT PROTEINS AND THEIR VARIANTS AS LYMPHOCYTARY EFFECTS AGAINST CANCER
CA2158455A1 (en) Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
CA2230885A1 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
CY1113379T1 (en) KDR Peptides and Vaccines Included
WO1998004702A3 (en) Proteins, in particular membrane proteins, of helicobacter pylori, their preparation and use
KR20120054644A (en) Dimerized peptide
CN105939723A (en) Composition for treating prostate cancer
ES2398492T3 (en) Fusion proteins comprising the tumor rejection antigens NY-ESO-1 and LAGE-1
DE69007616D1 (en) PEPTIDE, IMMUNOGENOUS COMPOSITION AND VACCINE OR MEDICAL PREPARATION, A METHOD FOR IMMUNIZING A MAMMALY AGAINST LHRH AND METHOD FOR IMPROVING MEA.
JP2019537562A5 (en)
HUP0100267A2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
ZA959416B (en) Carrier protein having an adjuvant effect immunogenic complex containing it process for their preparation nuclofotide sequence and vaccine
US8309096B2 (en) Fusion protein
KR970701724A (en) Corpuscles of stannius protein (stanniocalcin)
KR102166549B1 (en) A Blood-Brain Barrier Penetrating Peptide, and the Conjugate Comprising The Same
PE20001287A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING AN ANTIGENIC PROTEIN WITH ANTITUMORAL EFFECT
BR9707142A (en) Purified polynucleotide, dna, vector, host cell, hybridoma cell line, monoclonal antibody, processes to produce exodus, to increase resistance to infection by human immunodeficiency virus (hiv), for treatment of human immunodeficiency virus (hiv) infection , for the protection of bone marrow progenitor cells against cytotoxic effects and for the treatment of myeloproliferative diseases, and the use of an exodus protein product.
AR053372A1 (en) IMMUNOLOGICAL PROTEINS OF LAWSONIA INTRACELLULARIS
CA2353802A1 (en) New protective antigen of group a streptococci
BR9908476A (en) Peptide, therapeutic composition, and, process to confer protective immunity to a patient, against s infection. pneumoniae
CN1404527A (en) TLP peptides and DNA sequences coding the same
HRP20110729T1 (en) PLASMIDS CODING FOR p185neu PROTEIN SEQUENCE VARIANTS AND THERAPEUTIC USES THEREOF
NO20011263L (en) Moraxella Catarrhalis BASBO34 polypeptides and uses thereof